메뉴 건너뛰기
PharmacoEconomics
Volumn 29, Issue 3, 2011, Pages 189-198
Sample size and power for cost-effectiveness analysis (Part 1)
Author keywords

[No Author keywords available]
Indexed keywords

ARTICLE; BLOOD PRESSURE VARIABILITY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; PARAMETER; PRIORITY JOURNAL; SAMPLE SIZE; WEIGHT CHANGE;
EID: 79951643200     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11585070-000000000-00000     Document Type: Article
Times cited : (44)
References (22)
  • 2
    • 79952681381 scopus 로고    scopus 로고
    • Sample size and power for cost-effectiveness analysis part 2: The effect of maximum willingness to pay
    • In press
    • Glick HA. Sample size and power for cost-effectiveness analysis (part 2): the effect of maximum willingness to pay. Pharmacoeconomics. In press
    • Pharmacoeconomics
    • Glick, H.A.1
  • 3
    • 0034994363 scopus 로고    scopus 로고
    • Analysis, sample size, and power for estimating incremental net health benefit from clinical trial data
    • DOI 10.1016/S0197-2456(01)00110-6, PII S0197245601001106
    • Willan AR. Analysis, sample size, and power for estimating incremental net health benefit from clinical trial data. Control Clin Trials 2001; 22: 228-37 (Pubitemid 32522469)
    • (2001) Controlled Clinical Trials , vol.22 , Issue.3 , pp. 228-237
    • Willan, A.R.1
  • 5
    • 0031900689 scopus 로고    scopus 로고
    • Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis
    • DOI 10.1177/0272989X9801800209
    • Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998; 18: S68-80 (Pubitemid 28175944)
    • (1998) Medical Decision Making , vol.18 , Issue.2 SUPPL.
    • Stinnett, A.A.1    Mullahy, J.2
  • 6
    • 0041807885 scopus 로고    scopus 로고
    • What is the price of life and why doesnt it increase at the rate of inflation
    • Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003; 163: 41
    • (2003) Arch. Intern. Med. , vol.163 , pp. 41
    • Ubel, P.A.1    Hirth, R.A.2    Chernew, M.E.3
  • 7
    • 2442717630 scopus 로고    scopus 로고
    • Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis
    • DOI 10.1002/hec.864
    • Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13: 437-52 (Pubitemid 38660393)
    • (2004) Health Economics , vol.13 , Issue.5 , pp. 437-452
    • Devlin, N.1    Parkin, D.2
  • 8
    • 6344260475 scopus 로고    scopus 로고
    • Use of cost-effectiveness analysis in health-care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge?
    • DOI 10.1111/j.1524-4733.2004.75003.x
    • Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decisionmaking: how are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7: 518-28 (Pubitemid 39390832)
    • (2004) Value in Health , vol.7 , Issue.5 , pp. 518-528
    • Eichler, H.-G.1    Kong, S.X.2    Gerth, W.C.3    Mavros, P.4    Jonsson, B.5
  • 9
    • 70349301818 scopus 로고    scopus 로고
    • Life in the balance
    • Cressy D. Life in the balance. Nature 2009; 461: 336-9
    • (2009) Nature , vol.461 , pp. 336-339
    • Cressy, D.1
  • 10
    • 67349270247 scopus 로고    scopus 로고
    • Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation
    • Dedes KJ, Matter-Walstra K, Schwenkglenks M, et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer 2009; 45: 1397-406
    • (2009) Eur. J. Cancer , vol.45 , pp. 1397-1406
    • Dedes, K.J.1    Matter-Walstra, K.2    Schwenkglenks, M.3
  • 11
    • 0035019379 scopus 로고    scopus 로고
    • Bayesian assessment of sample size for clinical trials of cost-effectiveness
    • DOI 10.1177/02729890122062514
    • O'Hagan A, Stevens JW. Bayesian assessment of sample size for clinical trials of cost-effectiveness. Med Decis Making 2001; 21: 219-30 (Pubitemid 32452766)
    • (2001) Medical Decision Making , vol.21 , Issue.3 , pp. 219-230
    • O'Hagan, A.1    Stevens, J.W.2
  • 12
    • 0035141792 scopus 로고    scopus 로고
    • Parameter solicitation for planning cost effectiveness studies with dichotomous outcomes
    • McIntosh MW, Ramsey SD, Berry K, et al. Parameter solicitation for planning cost effectiveness studies with dichotomous outcomes. Health Econ 2001; 10: 53-66
    • (2001) Health Econ. , vol.10 , pp. 53-66
    • McIntosh, M.W.1    Ramsey, S.D.2    Berry, K.3
  • 13
    • 0030836029 scopus 로고    scopus 로고
    • Confidence intervals for cost-effectiveness ratios: A comparison of four methods
    • DOI 10.10 02/(SICI)109 9-1050(19970 5)6:3<243::A ID-HEC269>3.0. CO;2-Z
    • Polsky D, Glick HA, Willke R, et al. Confidence intervals for cost effectiveness ratios: a comparison of four methods. Health Econ 1997; 6: 243-52 (Pubitemid 27296588)
    • (1997) Health Economics , vol.6 , Issue.3 , pp. 243-252
    • Polsky, D.1    Glick, H.A.2    Willke, R.3    Schulman, K.4
  • 14
    • 0031923902 scopus 로고    scopus 로고
    • Power and sample size calculations for stochastic cost-effectiveness analysis
    • DOI 10.1177/0272989X9801800210
    • Briggs AH, Gray AM. Power and sample size calculations for stochastic cost-effectiveness analysis. Med Decis Making 1998; 18: S81-92 (Pubitemid 28175945)
    • (1998) Medical Decision Making , vol.18 , Issue.2 SUPPL.
    • Briggs, A.H.1    Gray, A.M.2
  • 15
    • 0343352822 scopus 로고    scopus 로고
    • The design and analysis of stochastic cost-effectiveness studies for the evaluation of health care interventions
    • Stockholm: Stockholm School of Economics
    • Briggs A, Tambour M. The design and analysis of stochastic cost-effectiveness studies for the evaluation of health care interventions (Working Paper Series in Economics and Finance No. 234). Stockholm: Stockholm School of Economics, 1998
    • (1998) Paper Series in Economics and Finance No 234
    • Briggs, A.1    Tambour, M.2
  • 16
    • 0033064211 scopus 로고    scopus 로고
    • Power and sample size in cost-effectiveness analysis
    • DOI 10.1177/0272989X9901900312
    • LaskaEM,MeisnerM, Siegel C. Power and sample size in costeffectiveness analysis.Med Decis Making 1999; 19: 339-43 (Pubitemid 29321275)
    • (1999) Medical Decision Making , vol.19 , Issue.3 , pp. 339-343
    • Laska, E.M.1    Meisner, M.2    Siegel, C.3
  • 17
    • 0032892898 scopus 로고    scopus 로고
    • Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data
    • DOI 10.10 02/(SICI)109 9-1050(199 905)8:3<20 3::AID-HEC413>3.0. CO;2-7
    • Willan AR, O'Brien BJ. Sample sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data. Health Econ 1999; 8: 203-11 (Pubitemid 29219085)
    • (1999) Health Economics , vol.8 , Issue.3 , pp. 203-211
    • Willan, A.R.1    O'brien, B.J.2
  • 18
    • 0033624760 scopus 로고    scopus 로고
    • Power and sample size assessments for tests of hypotheses on cost-effectiveness ratios
    • DOI 10.10 02/(SICI)10 99-1050(20000 4)9:3<227::AI D-HEC509>3.0. CO;2-Z
    • Gardiner JC, Huebner M, Jetton J, et al. Power and sample size assessments for tests of hypotheses on cost-effectiveness ratios. Health Econ 2000; 9: 227-34 (Pubitemid 30248639)
    • (2000) Health Economics , vol.9 , Issue.3 , pp. 227-234
    • Gardiner, J.C.1    Huebner, M.2    Jetton, J.3    Bradley, C.J.4
  • 19
    • 77149156284 scopus 로고    scopus 로고
    • Value of information analyses of economic randomized controlled trials: The treatment of intermittent claudication
    • Koerkamp BG, Spronk S, Stijnen T, et al. Value of information analyses of economic randomized controlled trials: the treatment of intermittent claudication. Value Health 2010; 13: 242-50
    • (2010) Value Health , vol.13 , pp. 242-250
    • Koerkamp, B.G.1    Spronk, S.2    Stijnen, T.3
  • 20
    • 38949093845 scopus 로고    scopus 로고
    • An opportunity cost approach to sample size calculation in cost-effectiveness analysis
    • DOI 10.1002/hec.1244
    • Gafni A, Walter SD, Birch S, et al. An opportunity cost approach to sample size calculation in cost-effectiveness analysis. Health Econ 2008; 17: 99-107 (Pubitemid 351227529)
    • (2008) Health Economics , vol.17 , Issue.1 , pp. 99-107
    • Gafni, A.1    Walter, S.D.2    Birch, S.3    Sendi, P.4
  • 21
    • 0031850669 scopus 로고    scopus 로고
    • Sample size calculation in economic evaluations
    • DOI 10.100 2/(SICI)109 9-1050(19980 6)7:4<327::AI D-HEC342>3.0. CO;2-U
    • Al MJ, Van Hout BA, Michel BC, et al. Sample size calculation in economic evaluations. Health Econ 1998; 7: 327-35 (Pubitemid 28339961)
    • (1998) Health Economics , vol.7 , Issue.4 , pp. 327-335
    • Al, M.J.1    Van Hout, B.A.2    Michel, B.C.3    Rutten, F.F.H.4

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.